alt51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

September 17-20, 2011, Chicago

ICAAC 2011: Raltegravir is Effective and Well-tolerated in Diverse Populations with HIV

The HIV integrase inhibitor raltegravir (Isentress) works well for both men and women and people of diverse racial/ethnic groups, according to data from the REALMRK trial presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) this week in Chicago.alt

Read more:

ICAAC 2011: Didanosine, Higher HCV Viral Load Predict Liver Fibrosis in HIV/HCV Coinfected People

Use of didanosine (ddI, Videx) -- along with higher hepatitis C virus (HCV) RNA level, male sex, and older age -- was a significant risk factor for liver fibrosis in people with HIV/HCV coinfection, researchers reported at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) this week in Chicago.alt

Read more:

ICAAC 2011: HCV Drug Telaprevir Shows No Problematic Interactions with Raltegravir

The new hepatitis C virus (HCV) protease inhibitor telaprevir (Incivek) does not appear to have clinically relevant drug-drug interactions with the HIV integrase inhibitor raltegravir (Isentress), according to a study presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.alt

Read more:

ICAAC 2011: BMS-790052 plus Standard Therapy Cures Most Genotype 1 Hepatitis C Patients

Up to 83% of treatment-naive people with difficult-to-treat genotype 1 hepatitis C virus (HCV) infection achieved sustained virological response (SVR) with the experimental HCV NS5A inhibitor BMS-790052 plus pegylated interferon and ribavirin, according to data presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) this week in Chicago.alt

Read more: